Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CX3CR1 | P49238 | 19/20 | 0.81 |
| ▸ | CXCR2 | P25025 | 17/20 | 0.81 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1588753 | 1.00 | CX3CR1 (0.81) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL212862 | 0.89 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL29473543 | 0.89 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL212398 | 0.89 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL31643602 | 0.89 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL23528828 | 0.89 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL30914115 | 0.89 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL30914151 | 0.89 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL213194 | 0.89 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL214469 | 0.89 | CXCR2 (0.82) | CX3CR1CXCR2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947693-B2 | 2R)-2-[(2-amino-5-{[(1S)-1-(2-fluorophenyl)ethyl]thio}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]pentan-1-ol; neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases su COPD, asthma | ASTRAZENECA AB (SE) | 2011-05-24 | — | — | US | disclosed |
| US-20080214578-A1 | Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 | ACTURUM REAL ESTATE AB (SE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214578-A1 | Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 | CX3CR1, CCR2, CXCR3 | CX3CR1 1/4885CXCR2 11/4885ADORA1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.